Compare · GKOS vs MDLN
GKOS vs MDLN
Side-by-side comparison of Glaukos Corporation (GKOS) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GKOS and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 4.9x GKOS ($9.77B).
- Both names hit the wire about 7 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- Glaukos Corporation
- Medline Inc.
- Price
- $164.87-0.58%
- $35.95-1.74%
- Market cap
- $9.77B
- $48.08B
- 1M return
- +2.12%
- -
- 1Y return
- +88.96%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- 2025
- News (4w)
- 7
- 7
- Recent ratings
- 25
- 25
Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Latest GKOS
- Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
- Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
- SEC Form 4 filed by Glaukos Corporation
- Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
- Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
- CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $249,158 worth of shares (1,615 units at $154.28) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 70,818 units (SEC Form 4)
- Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
- CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $243,204 worth of shares (1,457 units at $166.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 72,433 units (SEC Form 4)
- CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $2,483,104 worth of shares (13,744 units at $180.67), decreasing direct ownership by 16% to 73,890 units (SEC Form 4)
- Director Kliman Gilbert H exercised 2,500 shares at a strike of $25.77 and sold $475,000 worth of shares (2,500 units at $190.00) (SEC Form 4)
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M